Homepage Top Section1

The approval allows adults with SLE on standard therapy to inject Saphnelo themselves. It is supported by results from the Phase III TULIP-SC trial, which demonstrated that subcutaneous

Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix’s expertise in radiopharmaceutical platforms, global

According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial

Supported by Enterprise Singapore, the initiative aims to enhance Biophytis’ computational longevity platform and develop therapies for age-related diseases such as sarcopenia. The collaboration builds on Biophytis’ ongoing

The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low-

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage. JS001sc is independently developed by Junshi Biosciences as a subcutaneous

CordenPharma Colorado will occupy the entire premises under a 15-year lease. The new LEED Gold-certified facility has flexible laboratory configurations, advanced mechanical and utility systems, and waste management

Following completion, the combined entity will operate as Candid Therapeutics and list on Nasdaq under the “CDRX” ticker symbol. As part of the merger, Candid has secured more